Qimanguli Saiding, MS, PhD
NAD+-Nanoparticles for Klotho mRNA Delivery for Osteoarthritis Therapy
Abstract
This research advances novel drug delivery technology by developing NAD+ precursor-incorporating nanoparticles that perfectly aligns with the Foundation’s goal of enhanced delivery modalities for complex therapeutics. Our dual anti-aging therapy for osteoarthritis combines Klotho mRNA delivery with NAD+ metabolism enhancement, targeting the most common joint disease that currently lacks disease-modifying treatments. The approach addresses challenging formulation issues by simultaneously delivering two complementary therapeutic elements: a-Klotho mRNA, a large molecule that requires specialized delivery systems to maintain stability and achieve targeted expression; and NAD+ precursors, integrated directly into the nanoparticle structure to improve pharmacokinetics and pharmacodynamics in joint tissues. This project will optimize formulation composition for efficient mRNA delivery to joint tissues and employ predictive approaches to correlate in vitro performance with in vivo efficacy.
The PhRMA Foundation fellowship supports my pursuit of fundamental delivery science questions, bridging materials engineering and molecular biology to unlock new possibilities in mRNA therapeutics.
